IMUXbenzinga

Immunic Announces Addl Data From Phase 2 CALLIPER Trial In Progressive MS, Supporting Recently Released Top-Line Results and Underlining Vidofludimus Calcium's Neuroprotective Potential

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on June 5, 2025 by benzinga